DEFA14A: Neuphoria Defends Board Amidst Lynx1 Proxy Battle

Neuphoria Therapeutics Inc. issued statements to counter what it believes are deceptive claims by activist investor Lynx1 Master Fund LP, urging stockholders to support its current board nominees.

Summary

• Neuphoria is actively refuting claims made by activist investor Lynx1 Master Fund LP, characterizing them as "fictions" and a "campaign of deception and distraction."
• The company urges stockholders to vote FOR its nominees, Peter Miles Davies and David Wilson, on the WHITE proxy card, and WITHHOLD on both of Lynx1's nominees.
• Neuphoria asserts that Lynx1's outreach was aggressive and unsolicited, not following standard procedures, and that Lynx1's nominees lack relevant experience in neuropsychiatric disorders, investment banking, and M&A for life sciences.
• The record date of October 15, 2025, was set in September 2025 and publicly disclosed prior to Lynx1 launching their proxy contest.
• The company has not yet determined to proceed with the PTSD Phase 3 trial, but it remains an option, contrary to Lynx1's questioning of the plan.
• Neuphoria initiated a cost-cutting program and appointed a financial advisor for a strategic review before or simultaneously with recent clinical trial results, refuting claims of systemic failure.
• WG Partners LLP (WGP), associated with nominee David Wilson, receives a monthly flat fee for financial advisory services, explicitly stating it has no connection to the ATM program, countering Lynx1's conflict of interest claims.
• Lynx1's acquisition offer was based on 3.3 million shares outstanding, not 2.3 million as Lynx1 later claimed, suggesting a lack of due diligence or deliberately misleading statements.
• Neuphoria defends its nominees' qualifications, citing Mr. Davies' more than 15 years in investment banking and Mr. Wilson's more than 40 years in investment banking, 30 of which has been in Life Sciences, and leadership roles.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the failure of a key Phase 3 clinical trial and the ongoing proxy contest with an activist investor. However, the company is actively pursuing a strategic review, implementing cost-cutting measures, and robustly defending its board and strategy, which mitigates a lower score.

Positives

• Neuphoria has initiated a cost-cutting program to preserve cash.
• A strategic review process is well underway with a financial advisor (H.C. Wainwright & Co.) to explore all strategic alternatives.
• The company maintains a strong cash balance sheet, which is seen as valuable for strategic negotiations.
• Neuphoria's board nominees, Peter Miles Davies and David Wilson, possess extensive experience in investment banking, equity capital markets, strategic planning, and M&A within the life sciences sector.
• The company has an existing strategic partnership with Merck & Co., Inc. for two early-stage drugs in Alzheimer's disease and other central nervous system conditions.

Negatives

• The AFFIRM-1 Phase 3 clinical trial for BNC210 in social anxiety disorder missed its primary and secondary endpoints.
• Development of BNC210 in social anxiety disorder has been halted.
• The company is engaged in a proxy contest with activist investor Lynx1 Master Fund LP, creating uncertainty and requiring significant management attention.
• Lynx1 made a non-binding proposal to acquire all outstanding shares, which Neuphoria implies was disingenuous or lacked due diligence.

Risks

• Uncertainty regarding the outcome of the ongoing strategic alternatives review process.
• Risks inherent in developing and expanding the business, successfully completing development of product candidates, and the timing and outcome of clinical trials.
• Market risks for drugs to treat central nervous system diseases and pain conditions.
• Financial resource risks and capital allocation strategy.
• Risks associated with the Board's review of strategic alternatives and evaluation of offers from third parties.
• Potential for Lynx1's nominees, if elected, to support Lynx1's interests over those of all stockholders.
• Reliance on third parties for contracts, licenses, and arrangements, and their respective clinical trial and research and development projects.

Future Outlook

Neuphoria is currently conducting a strategic review to analyze and contemplate all strategic alternatives following the disappointing Phase 3 trial results. The option to proceed with a PTSD Phase 3 trial for BNC210 has not been ruled out. The company also continues to advance its strategic partnership with Merck & Co., Inc. for two early-stage drugs and its 7 nicotinic acetylcholine receptor next generation and Kv3.1/3.2 preclinical programs.

Management Comments

• "Neuphoria strongly believes is a campaign from Lynx1 Master Fund LP full of deception and distraction to deflect attention from its own limitations and its handpicked nominees shortcomings."
• "The Company urges stockholders to trust Neuphorias commitment to transparency and value creation over what it believes are Lynx1s fabrications and misdirection."
• "Lynx1s handpicked nominees lack understanding in the value of the Company, have no expertise to navigate complex strategic alternatives and continue to attempt to disrupt the Companys robust and active ongoing strategic alternatives review process."
• "The Board has already taken decisive actions, set clear priorities, and communicated near-term and long-term expectations to the market – not the least of which is to analyze and contemplate ALL STRATEGIC ALTERNATIVES, NOT BLINDLY LIMITING WHAT OPTIONS AND STRATEGIC ALTERNATIVES EXIST."
• "Lynx1s failure to understand [the value of a strong cash balance sheet] shows that they have little business running a public company or challenging the existing Board members."
• "We strongly recommend that Neuphoria stockholders vote FOR BOTH of Neuphorias nominees on the WHITE proxy card and vote WITHHOLD on BOTH of Lynx1s nominees."

Industry Context

The biotechnology industry is characterized by high-risk, high-reward drug development, where clinical trial failures are common and can significantly impact company valuation. Such setbacks often trigger strategic reviews and can attract activist investors, as seen with Lynx1's proxy contest. The emphasis on a strong balance sheet for strategic negotiations is a common theme in the sector, especially for clinical-stage companies navigating post-trial results.

Comparison to Industry Standards

• This filing primarily addresses a corporate governance dispute and a proxy contest rather than operational or financial performance metrics that can be directly compared to industry standards or specific competitor projects.
• While the company is a clinical-stage biotech, the document does not provide sufficient data on drug efficacy, market share, or R&D spending to benchmark against peers like Biogen, Sage Therapeutics, or Acadia Pharmaceuticals in the neuropsychiatric space.
• The focus is on defending the board's qualifications and strategic direction against an activist investor's claims, which is a common occurrence in the biotech sector following significant clinical or financial events.

Corporate Governance

Related Party Transactions

• WG Partners LLP (WGP), where David Wilson serves as Chair and founding partner, receives a monthly flat fee for financial advisory services from Neuphoria. The company explicitly states this fee has "ZERO connection to the ATM program."

Stakeholder Impact

• Shareholders: Directly impacted by the outcome of the proxy contest, the strategic review, and the potential for future value creation or destruction. They are being solicited to vote.
• Employees: Potential impact from the cost-cutting program and the uncertainty surrounding the strategic review.
• Customers/Patients: Future availability of BNC210 for PTSD is uncertain, and development for social anxiety disorder has halted.
• Creditors: Impacted by the company's financial health, cash preservation efforts, and strategic direction.

Next Steps

• Stockholders are urged to vote FOR Neuphoria's nominees (Peter Miles Davies and David Wilson) on the WHITE proxy card and WITHHOLD on Lynx1's nominees.
• The company will continue its robust and active ongoing strategic alternatives review process.
• The Board will analyze and contemplate all strategic alternatives.
• The option to proceed with the PTSD Phase 3 trial for BNC210 has not been ruled out.

Key Dates

Recommendation

A 'hold' recommendation is appropriate given the significant uncertainty surrounding Neuphoria Therapeutics Inc. The company faces a critical juncture with the failure of its Phase 3 clinical trial for BNC210 in social anxiety disorder, which has led to halted development in that indication. Concurrently, it is embroiled in a contentious proxy contest with activist investor Lynx1 Master Fund LP, challenging the current board's composition and strategic direction. While management is actively pursuing a strategic review and cost-cutting measures, the outcome of both the proxy vote and the strategic alternatives process remains unknown. Investors should await further clarity on the company's future strategic path and board composition before making definitive investment decisions.

Keywords

Neuphoria Therapeutics, NEUP, biotechnology, neuropsychiatric disorders, proxy contest, activist investor, Lynx1 Master Fund, SEC filing, strategic review, clinical trial, BNC210, PTSD, social anxiety disorder, corporate governance, board nominees, investment banking, capital markets, Merck partnership